
NEJM Journal Watch
@jwatch
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.
ID: 25952049
http://www.jwatch.org 23-03-2009 04:22:46
13,13K Tweet
60,60K Followers
118 Following









Conjunctival swabs were collected and tested from 194 children with acute infectious conjunctivitis and 196 age-matched controls. Of 52 tested pathogens, only one was associated with conjunctivitis. Read more: jwat.ch/4mkfc9w #conjunctivitis Clement Lee, MD, MSc #pediatrics





A high lipoprotein(a) [Lp(a)] level increases the risk for a first atherosclerotic cardiovascular disease (ASCVD) event, but what about the risk for recurrent events? jwat.ch/3SoAV2o #ASCVD Shea Hogan
![NEJM Journal Watch (@jwatch) on Twitter photo A high lipoprotein(a) [Lp(a)] level increases the risk for a first atherosclerotic cardiovascular disease (ASCVD) event, but what about the risk for recurrent events? jwat.ch/3SoAV2o
#ASCVD <a href="/SheaHogan7/">Shea Hogan</a> A high lipoprotein(a) [Lp(a)] level increases the risk for a first atherosclerotic cardiovascular disease (ASCVD) event, but what about the risk for recurrent events? jwat.ch/3SoAV2o
#ASCVD <a href="/SheaHogan7/">Shea Hogan</a>](https://pbs.twimg.com/media/GsHlLTpaUAA2vVN.jpg)

NEJM Group’s coverage of the American Society of Clinical Oncology Annual Meeting begins with a preview from three of our oncology experts: Dr. Robert Dreicer, Dr. ILSON David, and Dr. Michael Williams. jwat.ch/3ZCrUqo #ASCO25

The CDC recommends doxycycline postexposure prophylaxis (doxyPEP) for preventing bacterial STIs among high-risk people, but antimicrobial resistance is a concern. Researchers assessed doxyPEP's collateral effects. jwat.ch/3ZFL9zk #IDTwitter Carlos del Rio





A new systematic review suggests that noninvasive ventilation (NIV) might benefit some patients with acute asthma exacerbations. jwat.ch/3ZBCGgv Raja-Elie Abdulnour


Dr. Inas Abuali talks with Dr. Komal Jhaveri about the INAVO120 trial, which showed better overall survival when inavolisib was added to palbociclib–fulvestrant in patients with PIK3CA-mutated advanced breast cancer. jwat.ch/4kJhgGG Inas Abuali, MD #ASCO25 #bcsm Komal Jhaveri